200 related articles for article (PubMed ID: 33660365)
1. A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition.
Benslimane Y; Sánchez-Osuna M; Coulombe-Huntington J; Bertomeu T; Henry D; Huard C; Bonneil É; Thibault P; Tyers M; Harrington L
Aging Cell; 2021 Apr; 20(4):e13331. PubMed ID: 33660365
[TBL] [Abstract][Full Text] [Related]
2. p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells.
Shen H; Maki CG
J Cell Biochem; 2010 Dec; 111(5):1280-90. PubMed ID: 20803550
[TBL] [Abstract][Full Text] [Related]
3. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
[TBL] [Abstract][Full Text] [Related]
4. Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells.
Bashash D; Ghaffari SH; Mirzaee R; Alimoghaddam K; Ghavamzadeh A
Leuk Lymphoma; 2013 Mar; 54(3):561-8. PubMed ID: 22957790
[TBL] [Abstract][Full Text] [Related]
5. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
6. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
7. Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.
Celeghin A; Giunco S; Freguja R; Zangrossi M; Nalio S; Dolcetti R; De Rossi A
Cell Death Dis; 2016 Dec; 7(12):e2562. PubMed ID: 28032863
[TBL] [Abstract][Full Text] [Related]
8. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
[TBL] [Abstract][Full Text] [Related]
9. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
[TBL] [Abstract][Full Text] [Related]
10. Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients.
Trino S; Iacobucci I; Erriquez D; Laurenzana I; De Luca L; Ferrari A; Ghelli Luserna Di Rorà A; Papayannidis C; Derenzini E; Simonetti G; Lonetti A; Venturi C; Cattina F; Ottaviani E; Abbenante MC; Russo D; Perini G; Musto P; Martinelli G
Oncotarget; 2016 Mar; 7(11):12951-61. PubMed ID: 26887044
[TBL] [Abstract][Full Text] [Related]
11. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
12. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.
Gu L; Zhu N; Findley HW; Zhou M
Leukemia; 2008 Apr; 22(4):730-9. PubMed ID: 18273046
[TBL] [Abstract][Full Text] [Related]
13. Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence.
Luo H; Yount C; Lang H; Yang A; Riemer EC; Lyons K; Vanek KN; Silvestri GA; Schulte BA; Wang GY
Lung Cancer; 2013 Aug; 81(2):167-73. PubMed ID: 23683497
[TBL] [Abstract][Full Text] [Related]
14. A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation.
Valentine JM; Kumar S; Moumen A
BMC Cancer; 2011 Feb; 11():79. PubMed ID: 21338495
[TBL] [Abstract][Full Text] [Related]
15. Role of p53 transcription factor in determining the efficacy of telomerase inhibitors in cancer treatment.
Gala K; Jain M; Shah P; Pandey A; Garg M; Khattar E
Life Sci; 2024 Feb; 339():122416. PubMed ID: 38216120
[TBL] [Abstract][Full Text] [Related]
16. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Mueller S; Hartmann U; Mayer F; Balabanov S; Hartmann JT; Brummendorf TH; Bokemeyer C
Invest New Drugs; 2007 Dec; 25(6):519-24. PubMed ID: 17534576
[TBL] [Abstract][Full Text] [Related]
17. Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia.
Kaindl U; Morak M; Portsmouth C; Mecklenbräuker A; Kauer M; Zeginigg M; Attarbaschi A; Haas OA; Panzer-Grümayer R
Leukemia; 2014 Mar; 28(3):600-8. PubMed ID: 24240203
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
19. Chromosomal end fusion resulting from telomere erosion increases susceptibility to radiation via multinucleation: effect of p53.
Ju YJ; Park JE; Juhn KM; Jeong J; Yun M; Park MJ; Park GH; Choi KY; Cho MH; Wong KK; Park WB; Lee KH
Int J Oncol; 2006 Oct; 29(4):753-63. PubMed ID: 16964373
[TBL] [Abstract][Full Text] [Related]
20. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
